Skip to main content
    E

    Evaxion Biotech AS (EVAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.77
    +0.03 (+1.09%)

    Market Cap: $25.27M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Evaxion Biotech AS (EVAX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Evaxion Biotech AS (EVAX) to earn -$0.04 per share in the fiscal year ending Dec 31, 2026. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.02.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy125.0%
    Buy375.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$0.04
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$0.02
    EPS consensus, revenue $4.67M
    Fiscal year ending Dec 31, 2028
    -$0.03
    EPS consensus, revenue $24.04M
    Next report
    Nov 19, 2026
    Confirmed, before the open

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.04-$0.04 to -$0.042N/AN/A4
    Dec 31, 2027-$0.02-$0.03 to $0.002$4.67MN/A4
    Dec 31, 2028-$0.03-$0.24 to $0.182$24.04M$24.04M to $24.04M3

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.41-$0.45 to -$0.364

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202701

    EPS Trend

    The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.04-$0.04-$0.04-$0.04-$0.04N/A
    Fiscal year ending Dec 31, 2027-$0.02-$0.02-$0.02-$0.02$0.04N/A

    Frequently Asked Questions About EVAX

    What is the EVAX stock forecast?

    Consensus analyst estimates put Evaxion Biotech AS's EPS at -$0.04 for the fiscal year ending Dec 31, 2026. The consensus rating from 4 analysts is Buy.

    How do analysts rate EVAX stock?

    Of 4 analysts covering Evaxion Biotech AS, 1 rates it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from EVAX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.04, with estimates from -$0.04 to -$0.04 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.02, with estimates from -$0.03 to $0.00 from 2 analysts.

    What revenue do analysts expect from Evaxion Biotech AS next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $4.67M. For the fiscal year ending Dec 31, 2028, the consensus revenue estimate is $24.04M, with estimates from $24.04M to $24.04M.

    How many analysts cover EVAX?

    4 analysts rate Evaxion Biotech AS stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.